Success Metrics

Clinical Success Rate
92.2%

Based on 235 completed trials

Completion Rate
92%(235/255)
Active Trials
5(2%)
Results Posted
34%(80 trials)
Terminated
20(7%)

Phase Distribution

Ph phase_1
117
41%
Ph not_applicable
22
8%
Ph phase_2
83
29%
Ph early_phase_1
1
0%
Ph phase_4
18
6%
Ph phase_3
36
13%

Phase Distribution

118

Early Stage

83

Mid Stage

54

Late Stage

Phase Distribution277 total trials
Early Phase 1First-in-human
1(0.4%)
Phase 1Safety & dosage
117(42.2%)
Phase 2Efficacy & side effects
83(30.0%)
Phase 3Large-scale testing
36(13.0%)
Phase 4Post-market surveillance
18(6.5%)
N/ANon-phased studies
22(7.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.3%

235 of 266 finished

Non-Completion Rate

11.7%

31 ended early

Currently Active

5

trials recruiting

Total Trials

285

all time

Status Distribution
Active(5)
Completed(235)
Terminated(31)
Other(14)

Detailed Status

Completed235
Terminated20
unknown14
Withdrawn11
Recruiting4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
285
Active
5
Success Rate
92.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.4%)
Phase 1117 (42.2%)
Phase 283 (30.0%)
Phase 336 (13.0%)
Phase 418 (6.5%)
N/A22 (7.9%)

Trials by Status

completed23582%
terminated207%
withdrawn114%
active_not_recruiting10%
recruiting41%
unknown145%

Recent Activity

Clinical Trials (285)

Showing 20 of 285 trialsScroll for more
NCT05965726Phase 2

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

Completed
NCT05150691Phase 1

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Recruiting
NCT04518228

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Completed
NCT03194165

Population Pharmacokinetics of Antiretroviral in Children

Completed
NCT05576662Phase 2

Paxlovid for Treatment of Long Covid

Completed
NCT02470650Phase 4

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Withdrawn
NCT05386472Phase 1

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

Terminated
NCT05261139Phase 3

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Recruiting
NCT04960202Phase 2

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Completed
NCT06428045Phase 1

STARLITE for Unresectable High-Grade Gliomas

Recruiting
NCT03593954Phase 1

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Completed
NCT06710990Phase 1

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Recruiting
NCT04208061Phase 1

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Completed
NCT02259855Phase 1

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Completed
NCT05668091Phase 2

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Completed
NCT01400412Phase 2

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Completed
NCT05567952Phase 2

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Completed
NCT02275780Phase 3

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Completed
NCT05438602Phase 2

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

Completed
NCT05679388Phase 1

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
285